Company intelligence
AstraZeneca
About AstraZeneca
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio
Verified activity
Signals from AstraZeneca
141 published signals
Presence & Recognition
AstraZeneca leaders share their vision for how continued scientific progress could transform what is possible by 2040 as they head into WCLC 2026
Reported by AstraZeneca
Presence & Recognition
AstraZeneca is reflecting on the future of lung cancer care ahead of WCLC 2026.
Reported by sharon feeny
Research & Knowledge
AstraZeneca and partner Amgen announced positive high-level Phase III results from the DeLLphi-305 trial in extensive-stage small cell lung cancer.
Reported by Mohit Manrao
Research & Knowledge
AstraZeneca published findings from the OBERON and TITANIA Phase III trials, adding to evidence supporting a potential biologic treatment for chronic obstructive pulmonary disease.
Reported by Robert Fogel, MD
Strategy & Corporate Development
AstraZeneca achieved its bold hematology ambition at AstraZeneca by continuing to listen to patient voices and addressing inequities in care.
Reported by Mohit Manrao
Research & Knowledge
AstraZeneca is working on potential new treatment options and combinations to support lung cancer care.
Reported by Steve Sweet
Research & Knowledge
AstraZeneca is working on advances in biomarker testing to support lung cancer care.
Reported by Steve Sweet
Research & Knowledge
AstraZeneca is working on precision medicine therapeutics to support lung cancer care.
Reported by Steve Sweet
Partnerships
AstraZeneca is partnering with healthcare systems to tackle lung health inequities.
Reported by Rachel Payne
Presence & Recognition
AstraZeneca launched its new Joint Declaration as part of the Speak Up for COPD coalition.
Reported by Rachel Payne
Research & Knowledge
AstraZeneca published a New Scientist article detailing its oncology strategy to eliminate cancer as a cause of death.
Reported by Stephen Valerio, MS
People
AstraZeneca is hiring for the Executive Reward team
Reported by Louise Sutton
Research & Knowledge
AstraZeneca published a New Scientist article by Susan Galbraith detailing the science behind a new approach to attack cancer from multiple angles, including antibody drug conjugates, radioconjugates, bispecifics, and immuno-oncology approaches.
Reported by Puja Sapra
People
AstraZeneca welcomed Elisabete while pregnant, allowing her to manage her workload, take maternity leave, and return to the same supportive team.
Reported by Araz Yekita
Research & Knowledge
AstraZeneca published an alternative visualization to UMAP for single-cell data.
Reported by 🎯 Ming "Tommy" Tang
Partnerships
AstraZeneca and the Speak Up for COPD Coalition developed the Joint Declaration to issue four priorities for policy reform regarding COPD survival rates and care.
Reported by Suffwan Eltom
Presence & Recognition
AstraZeneca Portugal published Elisabete's experience of maternity leave during her pregnancy.
Reported by Francisco Castro Caldas
Research & Knowledge
AstraZeneca published in Nature Chemical Biology shedding new light into mechanisms of response to a broad range of DNA-damage response (DDR) inhibitors.
Reported by Josep Forment
Presence & Recognition
AstraZeneca leaders at WCLC26 shared insights on the future of lung cancer care.
Reported by Suzanne Bellomo
Partnerships
AstraZeneca and the Speak Up for COPD Coalition developed the Joint Declaration to issue four priorities for policy reform regarding COPD survival rates and care.
Reported by Andreas Heddini
Research & Knowledge
AstraZeneca announced full results from Phase III OBERON and TITANIA trials in chronic obstructive pulmonary disease, demonstrating reductions in moderate-to-severe exacerbations across all blood eosinophil counts and lung function stages.
Reported by Cesar Cerezo
Partnerships
AstraZeneca colleagues are part of Consultorio Amazonas, a programme combining AI and chest x-rays to prioritize high-risk patients for CT scan
Reported by Luis Fernando Ribeiro
Research & Knowledge
AstraZeneca published an article in MIT Technology Review exploring how AI is embedded across biologics discovery to identify potential new biologics for development in weeks instead of months.
Reported by Luis Fernando Ribeiro
Research & Knowledge
AstraZeneca and Amgen announced positive high-level results from the DeLLphi-305 Phase III trial in extensive-stage small cell lung cancer for patients who had not progressed after treatment with their IO medicine plus chemotherapy.
Reported by Nancy Ghattas